文献速递毛发、甲与色素性疾病

亚临床致敏的DPCP方案治疗159例斑秃的回顾性分析

Subclinical sensitization with diphenylcyclopropenone is sufficient for the treatment of alopecia areata: Retrospective analysis of 159 cases.
PubMed 文献 · J Am Acad Dermatol · 2017-11-03

该回顾性研究纳入159例接受改良二苯环丙烯酮(DPCP)方案治疗的斑秃患者,先以0.1%致敏、0.01%起始并缓慢递增浓度。46例(28.9%)完全缓解,59例(37.1%)部分缓解;致敏后无不良反应,治疗中仅3例(1.9%)出现严重不良反应,且均可通过抗组胺药或联合中等强度外用激素控制。

要点

  • 改良DPCP亚临床致敏方案可诱导较好的毛发再生反应
  • 致敏后未见不良反应,治疗中严重不良反应仅1.9%
  • 不良反应与治疗反应之间无关联

核心结论

  • 采用亚临床致敏的改良DPCP方案可诱导有利的治疗反应并减少不良反应。

研究设计与样本

  • 回顾性分析159例斑秃患者,所有患者以0.1% DPCP致敏,并以0.01% DPCP起始治疗,之后根据治疗反应和不良反应缓慢增加浓度。

主要发现

  • 159例中46例(28.9%)完全缓解,59例(37.1%)部分缓解。
  • 致敏后无患者出现不良反应;治疗期间仅3例(1.9%)出现严重不良反应,55例出现中度不良反应。
  • 所有不良反应仅用抗组胺药或抗组胺药联合中等强度外用激素即可良好控制。
  • 治疗反应与不良反应之间无关联。

关键数值与推荐

  • 致敏浓度0.1% DPCP,起始治疗浓度0.01% DPCP,之后缓慢递增。
  • 完全缓解46/159(28.9%),部分缓解59/159(37.1%)。
  • 严重不良反应3/159(1.9%),中度不良反应55例。

临床怎么用

  • 对广泛性斑秃可采用亚临床致敏的改良DPCP方案,以在促进毛发再生的同时减少不良反应。
  • 治疗期间出现的中至重度不良反应可通过抗组胺药或联合中等强度外用激素控制。

局限性

  • 样本量、受试者构成及回顾性研究设计为潜在局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Contact immunotherapy with diphenylcyclopropenone (DPCP) is presently considered the treatment of choice for extensive alopecia areata. However, a major concern with contact immunotherapy is that it causes various adverse effects (AEs) that contribute to discontinuation of treatment. OBJECTIVE: We investigated whether a modified DPCP treatment protocol can promote hair regrowth with fewer AEs. METHODS: All patients were sensitized with 0.1% DPCP and began treatment with 0.01% DPCP. Thereafter, the DPCP concentration was slowly increased according to the treatment response and AEs. This was a retrospective review of DPCP treatment with modified protocols in 159 patients with alopecia areata. RESULTS: Of the 159 patients, 46 (28.9%) showed a complete response and 59 (37.1%) showed a partial response. No patients had AEs after sensitization. During the treatment, only 3 patients (1.9%) showed severe AEs, and 55 showed moderate AEs; however, all were well controlled with antihistamines alone or antihistamines and medium-potency topical steroids. There was no association between treatment response and AEs. LIMITATIONS: Sample size, subject composition, and the retrospective study design represent potential limitations. CONCLUSION: A modified DPCP treatment protocol with subclinical sensitization could induce a favorable therapeutic response and result in fewer AEs.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Choe SJ, Lee S, Pi LQ, et al. Subclinical sensitization with diphenylcyclopropenone is sufficient for the treatment of alopecia areata: Retrospective analysis of 159 cases. J Am Acad Dermatol. 2017. PMID: 29108907. doi:10.1016/j.jaad.2017.10.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。